| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/13/2011 | EP2307027A1 Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits |
| 04/13/2011 | EP2307026A1 The use of androgens for vascular regeneration and endothelial repair |
| 04/13/2011 | EP2307025A2 Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| 04/13/2011 | EP2307024A1 Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity |
| 04/13/2011 | EP2307023A1 Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase |
| 04/13/2011 | EP2307022A1 Enhanced nsaid formulations |
| 04/13/2011 | EP2307021A1 Formulations |
| 04/13/2011 | EP2307020A1 Administration regime for nitrocatechols |
| 04/13/2011 | EP2307019A1 Pharmaceutical compositions comprising gamma secretase modulators |
| 04/13/2011 | EP2307018A1 Oxymatrine compositions and use thereof for treating and preventing chronic infectious diseases |
| 04/13/2011 | EP2307017A1 Compounds which can be used for the treatment of cancers |
| 04/13/2011 | EP2307016A2 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivative or its salt, and bisphosphonate |
| 04/13/2011 | EP2307015A2 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt |
| 04/13/2011 | EP2307014A1 Synergistic antimicrobial mixtures |
| 04/13/2011 | EP2307013A1 Pain-relieving compositions of furoxan no donors and uses thereof |
| 04/13/2011 | EP2307012A1 Nitrogen heterocycle derivatives as proteasome modulators |
| 04/13/2011 | EP2307011A1 Use of isoindoles for the treatment of neurobehavioral disorders |
| 04/13/2011 | EP2307010A1 Thiazole compounds, and compositions and methods using same |
| 04/13/2011 | EP2307009A2 Composition comprising an association of active principles for use in the topical treatment of baldness |
| 04/13/2011 | EP2307008A1 Substituted indolyl and indazolyl derivatives and uses thereof |
| 04/13/2011 | EP2307007A1 Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation |
| 04/13/2011 | EP2307006A2 Pharmaceutical composition containing 1,2-dithiolthione derivative for preventing or treating disease caused by overexpression of lxr-alpha |
| 04/13/2011 | EP2307005A1 Taxifolin derivatives for the prophylaxis and treatment of neurological and psychiatric disorders of the central nervous system |
| 04/13/2011 | EP2307004A1 Novel treatments |
| 04/13/2011 | EP2307003A2 Combination therapy with pm00104 and another antitumor agent |
| 04/13/2011 | EP2307002A1 Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine |
| 04/13/2011 | EP2307001A1 Control of blood vessel physiology to treat skin disorders |
| 04/13/2011 | EP2307000A1 Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders |
| 04/13/2011 | EP2306999A2 Compositions for treating rosacea |
| 04/13/2011 | EP2306998A1 Pharmaceutical formulation |
| 04/13/2011 | EP2306997A1 Treatment of ringworm |
| 04/13/2011 | EP2306996A1 Use of hdac inhibitors for the treatment of hodgkin's disease |
| 04/13/2011 | EP2306995A1 Antitumor properties of no modified protease inhibitors |
| 04/13/2011 | EP2306994A1 S1p1 receptor agonists and use thereof |
| 04/13/2011 | EP2306992A2 Delivery particle |
| 04/13/2011 | EP2306990A1 Pharmaceutical composition comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1 h-pyrrole-3-carboxamide |
| 04/13/2011 | EP2306989A2 Fenofibrate formulation with enhanced oral bioavailability |
| 04/13/2011 | EP2306988A1 Pharmaceutical formulation for treating the upper digestive tract |
| 04/13/2011 | EP2306983A1 A gastroretentive pharmaceutical dosage form |
| 04/13/2011 | EP2306982A1 Pharmaceutical compositions of rosuvastatin calcium |
| 04/13/2011 | EP2306981A1 A transmucosal delivery system |
| 04/13/2011 | EP2306980A2 Powders for reconstitution |
| 04/13/2011 | EP2306977A1 Method and composition for treating ocular hypertension and glaucoma |
| 04/13/2011 | EP2306976A2 Injectable taxane pharmaceutical composition |
| 04/13/2011 | EP2306975A2 Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
| 04/13/2011 | EP2306971A1 Unit dosage of apadenoson |
| 04/13/2011 | EP2306847A2 Composition of branched maltodextrins and eukaryotic organisms having a polysaccharide wall, used in the field of well-being |
| 04/13/2011 | EP2306846A2 Composition of soluble indigestible fibre and of microalgae used in the well-being field |
| 04/13/2011 | EP2306843A1 Nutritional composition for infants delivered via caesarean section |
| 04/13/2011 | EP2306839A1 Gacyclidine formulations |
| 04/13/2011 | EP2306838A1 Methods of treating atherosclerosis |
| 04/13/2011 | EP2306836A1 Bmi-1 protein expression modulators |
| 04/13/2011 | EP2306828A1 Prolyl hydroxylase inhibitors |
| 04/13/2011 | EP2306826A1 Salts of methyl 2-((r))-(3-chlorophenyl)((r)-1-((s)-2-(methylamino)-3((r)-tetrahydro-2h-pyran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate |
| 04/13/2011 | EP2306825A1 Inhibitors of akt activity |
| 04/13/2011 | EP2306824A1 Iontophoretic delivery of curcumin and curcumin analogs for the treatment of alzheimer's disease |
| 04/13/2011 | EP2306823A1 Formulations of 5-fluorocytosine and uses thereof |
| 04/13/2011 | EP2215095B1 Cyclopropyl fused indolobenzazepine derivatives for the treatment of hepatitis c |
| 04/13/2011 | EP2205620B1 Amorphous form of (11beta,16alpha)-9-fluoro-11-hydroxy-16,17-[(1-methylethyliden)bis(oxy)]-21-[[4- [(nitrooxy)methyl]benzoyl]oxy]-pregna-1,4-dien-3,20-dione |
| 04/13/2011 | EP2195326B1 Nucleoside derivatives as inhibitors of viral polymerases |
| 04/13/2011 | EP2188252B1 1-(4-(4-benzylbenzamido)-benzyl)azetidine-3-carboxylic acid derivatives and related compounds as s1p receptor modulators for the treatment of immune disorders |
| 04/13/2011 | EP2176221B1 Indole indane amide compounds useful as cb2 agonists and method |
| 04/13/2011 | EP2125744B1 Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives |
| 04/13/2011 | EP2101778B1 Ectoin for treating vascular leaks |
| 04/13/2011 | EP2094690B1 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists |
| 04/13/2011 | EP2051714B1 Drug combinations for the treatment of respiratory tract diseases |
| 04/13/2011 | EP2018165B1 Fgf-peceptor agonist dimeric compounds |
| 04/13/2011 | EP2013198B1 Solid-state form of amg 706 and pharmaceutical compositions thereof |
| 04/13/2011 | EP1931636B1 Isoquinolines as igf-1r inhibitors |
| 04/13/2011 | EP1928886B1 Pyridine derivatives and their use in the treatment of psychotic disorders |
| 04/13/2011 | EP1926472B1 Stabilized and preserved ketotifen ophthalmic compositions |
| 04/13/2011 | EP1909800B1 Acylglycerophospholipids for treating symptoms concomitant with cancer |
| 04/13/2011 | EP1909795B1 Pharmaceutical composition for use in treating individuals exhibiting mutant kit protein |
| 04/13/2011 | EP1896466B1 N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| 04/13/2011 | EP1888064B1 Benztropinamine analogs as dopamine uptake inhibitors |
| 04/13/2011 | EP1797185B1 Targeting opposite strand replication intermediates of single-stranded viruses by rnai |
| 04/13/2011 | EP1796644B1 Drug delivery from embolic agents |
| 04/13/2011 | EP1781275B1 Sustained release pharmaceutical composition of tolterodine |
| 04/13/2011 | EP1778251B1 Nucleoside phosphonate conjugates as anti hiv agents |
| 04/13/2011 | EP1745046B1 1 h-indazoles, benzothiazoles, 1,2-benziosoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
| 04/13/2011 | EP1720531B1 New compositions containing quinoline compounds |
| 04/13/2011 | EP1713779B1 Indazole derivatives as inhibitors of hormone-sensitive lipases |
| 04/13/2011 | EP1572127B1 Enzyme treatment of foodstuffs for celiac sprue |
| 04/13/2011 | EP1542978B1 Novel bio-active molecules |
| 04/13/2011 | EP1539783B1 Inhibitors of nucleoside phosphorylases and nucleosidases |
| 04/13/2011 | EP1539763B1 Azaindole kinase inhibitors |
| 04/13/2011 | EP1480661B1 Micro/nanoparticle obtained from lipid-containing marine organisms for use in pharmaceutics and cosmetics |
| 04/13/2011 | EP1438026B1 Taste masking spill-resistant formulation |
| 04/13/2011 | EP1140085B1 Azabicycloalkanes as ccr5 modulators |
| 04/13/2011 | EP0957941B1 USE OF A MELANOMA DIFFERENTIATION ASSOCIATED GENE (mda-7) FOR REVERSING A CANCEROUS PHENOTYPE |
| 04/13/2011 | CN201790234U Disposable medical hand brush |
| 04/13/2011 | CN1993122B Cholesterol lowering supplement and low cholesterol egg produced by using the same |
| 04/13/2011 | CN1993116B Use of discharge protein inhibitors in preparing medicine for improving bioavailability of a renin inhibitor |
| 04/13/2011 | CN1980888B Modafinil compositions |
| 04/13/2011 | CN1958568B A kind of compound for preventing or curing infection of helicobacter pylori, preparation method, and application |
| 04/13/2011 | CN1946412B Preventive and/or remedy for inflammatory bowel diseases |
| 04/13/2011 | CN1939296B Theapolyphenol composition and its preparation |
| 04/13/2011 | CN1931205B Kindir leaf total flavone extract and its preparation and application |
| 04/13/2011 | CN1926109B Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| 04/13/2011 | CN1910293B Detection of mutations in a gene associated with resistance to viral infection, OASI |